 AstraZeneca Plc NASDAQ: AZN and Daiichi Sankyo OCTMKTS: DSNKY have announced an update from their second antibody-drug conjugate ADC program that is showing promise in hard-to-treat breast cancer. The ADC, datopotamab deruxtecan, posted a 43 response rate and five confirmed complete or partial responses among 21 patients with triple-negative breast cancer, according to cohort data from the TROPION-PanTumor01 Phase 1 study presented at the virtual ESMO Breast annual meeting 2021. 